Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study. Calabrò, L., Morra, A., Giannarelli, D., Amato, G., D'Incecco, A., Covre, A., Lewis, A., Rebelatto, M. C, Danielli, R., Altomonte, M., Di Giacomo, A. M., & Maio, M. The Lancet Respiratory Medicine, 2600(18):1–10, may, 2018. ![Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study. [link]](https://bibbase.org/img/filetypes/link.svg "link")
Paper doi bibtex @article{Calabro2018,
author = {Calabr{\`{o}}, Luana and Morra, Aldo and Giannarelli, Diana and Amato, Giovanni and D'Incecco, Armida and Covre, Alessia and Lewis, Arthur and Rebelatto, Marlon C and Danielli, Riccardo and Altomonte, Maresa and {Di Giacomo}, Anna Maria and Maio, Michele},
doi = {10.1016/S2213-2600(18)30151-6},
issn = {2213-2619},
journal = {The Lancet Respiratory Medicine},
month = {may},
number = {18},
pages = {1--10},
pmid = {29773326},
title = {{Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study.}},
url = {http://www.ncbi.nlm.nih.gov/pubmed/29773326},
volume = {2600},
year = {2018}
}
Downloads: 0
{"_id":"jbye8YuastucubW7q","bibbaseid":"calabr-morra-giannarelli-amato-dincecco-covre-lewis-rebelatto-etal-tremelimumabcombinedwithdurvalumabinpatientswithmesotheliomanibitmeso1anopenlabelnonrandomisedphase2study-2018","downloads":0,"creationDate":"2019-04-16T18:59:28.035Z","title":"Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study.","author_short":["Calabrò, L.","Morra, A.","Giannarelli, D.","Amato, G.","D'Incecco, A.","Covre, A.","Lewis, A.","Rebelatto, M. C","Danielli, R.","Altomonte, M.","Di Giacomo, A. M.","Maio, M."],"year":2018,"bibtype":"article","biburl":"http://raunakms.github.io/files/citations/raunak_shrestha_ubc_phd_thesis_bibliography_2018.bib","bibdata":{"bibtype":"article","type":"article","author":[{"propositions":[],"lastnames":["Calabrò"],"firstnames":["Luana"],"suffixes":[]},{"propositions":[],"lastnames":["Morra"],"firstnames":["Aldo"],"suffixes":[]},{"propositions":[],"lastnames":["Giannarelli"],"firstnames":["Diana"],"suffixes":[]},{"propositions":[],"lastnames":["Amato"],"firstnames":["Giovanni"],"suffixes":[]},{"propositions":[],"lastnames":["D'Incecco"],"firstnames":["Armida"],"suffixes":[]},{"propositions":[],"lastnames":["Covre"],"firstnames":["Alessia"],"suffixes":[]},{"propositions":[],"lastnames":["Lewis"],"firstnames":["Arthur"],"suffixes":[]},{"propositions":[],"lastnames":["Rebelatto"],"firstnames":["Marlon","C"],"suffixes":[]},{"propositions":[],"lastnames":["Danielli"],"firstnames":["Riccardo"],"suffixes":[]},{"propositions":[],"lastnames":["Altomonte"],"firstnames":["Maresa"],"suffixes":[]},{"propositions":[],"lastnames":["Di Giacomo"],"firstnames":["Anna","Maria"],"suffixes":[]},{"propositions":[],"lastnames":["Maio"],"firstnames":["Michele"],"suffixes":[]}],"doi":"10.1016/S2213-2600(18)30151-6","issn":"2213-2619","journal":"The Lancet Respiratory Medicine","month":"may","number":"18","pages":"1–10","pmid":"29773326","title":"Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study.","url":"http://www.ncbi.nlm.nih.gov/pubmed/29773326","volume":"2600","year":"2018","bibtex":"@article{Calabro2018,\n author = {Calabr{\\`{o}}, Luana and Morra, Aldo and Giannarelli, Diana and Amato, Giovanni and D'Incecco, Armida and Covre, Alessia and Lewis, Arthur and Rebelatto, Marlon C and Danielli, Riccardo and Altomonte, Maresa and {Di Giacomo}, Anna Maria and Maio, Michele},\n doi = {10.1016/S2213-2600(18)30151-6},\n issn = {2213-2619},\n journal = {The Lancet Respiratory Medicine},\n month = {may},\n number = {18},\n pages = {1--10},\n pmid = {29773326},\n title = {{Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study.}},\n url = {http://www.ncbi.nlm.nih.gov/pubmed/29773326},\n volume = {2600},\n year = {2018}\n}\n\n","author_short":["Calabrò, L.","Morra, A.","Giannarelli, D.","Amato, G.","D'Incecco, A.","Covre, A.","Lewis, A.","Rebelatto, M. C","Danielli, R.","Altomonte, M.","Di Giacomo, A. M.","Maio, M."],"key":"Calabro2018","id":"Calabro2018","bibbaseid":"calabr-morra-giannarelli-amato-dincecco-covre-lewis-rebelatto-etal-tremelimumabcombinedwithdurvalumabinpatientswithmesotheliomanibitmeso1anopenlabelnonrandomisedphase2study-2018","role":"author","urls":{"Paper":"http://www.ncbi.nlm.nih.gov/pubmed/29773326"},"downloads":0},"search_terms":["tremelimumab","combined","durvalumab","patients","mesothelioma","nibit","meso","open","label","non","randomised","phase","study","calabrò","morra","giannarelli","amato","d'incecco","covre","lewis","rebelatto","danielli","altomonte","di giacomo","maio"],"keywords":[],"authorIDs":[],"dataSources":["D26R22TtQkBrD8ZqL"]}